Alaunos Therapeutics, Inc. Common Stock

TCRTNASDAQUSD
2.05 USD
0.02 (0.97%)AT CLOSE (11:59 AM EDT)
2.23
0.18 (8.73%)
POST MARKET (AS OF 04:56 PM EDT)
Post Market
AS OF 04:56 PM EDT
2.23
0.18 (8.73%)
🔴Market: CLOSED

Shares of Alaunos Therapeutics, Inc. Common Stock (TCRT) are trading at $2.04. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$2.04
High?$2.06
Low?$2.02
Prev. Close?$2.07
Volume?4.7K
Avg. Volume?17.2K
VWAP?$2.04
Rel. Volume?0.27x
Bid / Ask
Bid?$1.72 × 100
Ask?$2.35 × 100
Spread?$0.63
Midpoint?$2.04
Valuation & Ratios
Market Cap?5.1M
Shares Out?24.4M
Float?1.9M
Float %?77.7%
P/E Ratio?N/A
P/B Ratio?3.92
EPS?-$1.79
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Employees
1
Market Cap
5.1M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2005-08-24
Address
501 E LAS OLAS BLVD
FORT LAUDERDALE, FL 33301
Phone: (346) 355-4099
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-690.13Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.79%Low
Short Interest?14.7K
Days to Cover?1.1
Free Float1.9M
Avg Daily Volume13.9K
Settlement Date2026-06-30
Financial Health
Current Ratio?1.63Adequate
Quick Ratio?1.63Adequate
Cash Ratio?0.59Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A
P/B?
Peers
100
S&P
45
3.92FAIR
P/S?
Peers
100
S&P
3
1,685.08HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.1CHEAP
EV/Sales?
Peers
100
S&P
3
1,567.08HIGH
Returns & Efficiency
ROE?
S&P
3
-338.8%WEAK
ROA?
S&P
3
-231.8%WEAK
Cash Flow & Enterprise
FCF?$-3226000
Enterprise Value?$4.7M
Fundamentals ratios updated end of day